Home Other Building Blocks 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide

3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide

CAS No.:
289893-25-0
Catalog Number:
AG002V3O
Molecular Formula:
C14H20ClN3O3
Molecular Weight:
313.7799
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG002V3O
Chemical Name:
3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide
CAS Number:
289893-25-0
Molecular Formula:
C14H20ClN3O3
Molecular Weight:
313.7799
MDL Number:
MFCD16660939
IUPAC Name:
(3Z)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride
InChI:
InChI=1S/C14H20ClN3O3/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17/h4-5,8-9,13,19H,1-3,6-7,10-11H2/b16-14-/t13-/m1/s1
InChI Key:
SGEIEGAXKLMUIZ-XUVDNFPMSA-N
SMILES:
O[C@H](CN1CCCCC1)CON=C(c1ccc[n+](c1)[O-])Cl
Properties
Complexity:
337  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
1  
Exact Mass:
313.119g/mol
Formal Charge:
0
Heavy Atom Count:
21  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
313.782g/mol
Monoisotopic Mass:
313.119g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
70.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.2  
Literature
Title Journal
Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 20120601
Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PloS one 20120101
Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs : the investigational drugs journal 20100701
Arimoclomol: a potential therapy under development for ALS. Expert opinion on investigational drugs 20091201
Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects. Cellular & molecular biology letters 20090101
Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. Journal of neurochemistry 20081001
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle & nerve 20080701
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature medicine 20040401
Putting the heat on ALS. Nature medicine 20040401
The effect of treatment with BRX-220, a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury. Experimental neurology 20031201
Upregulation of heat shock proteins rescues motoneurones from axotomy-induced cell death in neonatal rats. Experimental neurology 20020701
Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free radical biology & medicine 20020615
Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance. Annals of the New York Academy of Sciences 20020601
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. Annals of the New York Academy of Sciences 20020601
Properties